Polaryx Therapeutics (NASDAQ:PLYX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Polaryx Therapeutics (NASDAQ:PLYX) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

PLYX has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. HC Wainwright assumed coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 price target for the company. Raymond James Financial assumed coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target for the company. Finally, Zacks Research raised Polaryx Therapeutics to a “hold” rating in a report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Polaryx Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $7.67.

Polaryx Therapeutics Trading Up 1.0%

Shares of NASDAQ PLYX opened at $2.01 on Friday. The company has a market cap of $100.19 million and a price-to-earnings ratio of -25.12. Polaryx Therapeutics has a 12 month low of $1.85 and a 12 month high of $48.91. The stock has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $3.44.

Polaryx Therapeutics (NASDAQ:PLYX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. On average, sell-side analysts predict that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.